Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LXM.12
- Development stage
- Preclinical
- Lead developer
- Laxxon Medical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
LXM.12 is a preclinical-stage small molecule therapeutic being developed by Laxxon Medical for the treatment of prostate carcinoma. The drug is developed using Laxxon's proprietary 3D screen printing technology (SPIT), which allows for the creation of complex oral dosage forms with precise, controlled-release profiles. By leveraging this advanced manufacturing platform, LXM.12 aims to optimize the delivery and efficacy of its active pharmaceutical ingredient for patients with prostate cancer. As of 2024, the specific biological target and the identity of the small molecule have not been publicly disclosed, and the program remains in early-stage development.
Beyond the preview
Go deeper on LXM.12.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LXM.12.